

Opko Health, Inc.  
Form 8-K  
September 11, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2018

OPKO Health, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware                      001-33528      75-2402409  
(State or Other Jurisdiction   (Commission   (IRS Employer  
of Incorporation)              File Number)   Identification No.)

4400 Biscayne Blvd. Miami, Florida      33137  
(Address of Principal Executive Offices)   (Zip Code)  
Registrant's telephone number, including area code: (305) 575-4100

Not Applicable  
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 7.01. Regulation FD Disclosure.

On September 11, 2018, OPKO Health, Inc. (“OPKO” or the “Company”) issued a press release regarding Nasdaq’s decision to halt trading in OPKO’s common stock in connection with the lawsuit previously reported in the Company’s Current Report on Form 8-K filed on September 10, 2018 (the “Lawsuit”). A copy of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information included in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 8.01. Other Events.

On September 7, 2018, at 14:34:38 Eastern Daylight Time, Nasdaq halted trading in the Company’s common stock pending receipt from the Company of information requested by the exchange related to the allegations contained in the Lawsuit. Nasdaq has advised the Company that trading will remain halted until the exchange is satisfied with OPKO’s response to Nasdaq’s request for information

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release of the Company dated September 11, 2018

---

Exhibit List

Exhibit No. Description

99.1 Press Release of the Company dated September 11, 2018

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OPKO Health, Inc.

By: /s/ Adam Logal

Date: September 11, 2018 Name: Adam Logal

Title: Senior Vice President, Chief Financial Officer